Ross lands at Imatron

Article

It didn’t take long for Terry Ross, former president and CEO of PACS firm Cemax-Icon, to find a new job. Ross, who left the Fremont, CA-based firm following the close of its acquisition by Eastman Kodak in December (SCAN 12/16/98), has been

It didn’t take long for Terry Ross, former president and CEO of PACS firm Cemax-Icon, to find a new job. Ross, who left the Fremont, CA-based firm following the close of its acquisition by Eastman Kodak in December (SCAN 12/16/98), has been named president of ultrafast CT developer Imatron of South San Francisco, CA. He has served as an Imatron board member for 12 years.

Ross is the second Cemax-Icon executive to leave the company in recent months. Former vice president of sales and marketing Oran Muduroglu left the company in 1998 to head up Stentor, a San Francisco startup formed to commercialize dynamic transfer syntax (DTS), a protocol for low-cost enterprise-wide image distribution developed by a University of Pittsburgh Medical Center PACS research team. A DTS demonstration drew much attention in the infoRAD exhibit area at last year’s RSNA meeting.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.